Item 9 Labs

Item 9 Labs

Closed: Mar. 2023

About this raise

Item 9 Labs is raising funds on Dalmore Group through Reg A+ crowdfunding. The company makes and sells cannabis-derived products in licensed medical and adult-use dispensaries. The business also sells cannabis dispensary franchises under its franchise brand, Unity Rd. Item 9 Labs has won cannabis licenses in 17 states, over 45 cannabis and franchise industry awards, and more than 300 franchise awards in 15 countries. Andrew Bowden founded Item 9 Labs in 2010. The current crowdfunding campaign has no minimum target and a maximum target of $42,000,000. The campaign proceeds will be used for the acquisition of retail dispensary businesses, cultivation and production businesses, working capital, and general corporate purposes.

Expand

Investment Overview

Invested this round: $18,974

Deal Terms

Total Commitments ($USD)

Platform
Dalmore Group
Start Date
02/25/2022
Close Date
Not Provided
Min. Goal
$1,500
Max Goal
$42,000,000
Min. Investment

$1,500

Security Type

Equity - Common

Series

Series A

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$1.40

Pre-Money Valuation

$133,057,658

Company & Team

Company

Year Founded
2010
Industry
Alcohol, Tobacco, & Recreational Drugs
Tech Sector
Non-Tech
Distribution Model
B2B/B2C
Margin
Low
Capital Intensity
High
Location
Phoenix, Arizona
Business Type
Growth
Company Website
Visit Website

Team

Employees
105
Prior Founder Exits?
No
Founder Name
Bryce Skalla
Title
Ex-CEO
Founder Name
Sean Dugan
Title
Hemp Production
Founder Name
Andrew Poirier
Title
Director Of Research Development

Financials

 Revenue +170% YoY
$21,937,227
 Monthly Burn
$908,814
 Runway
1.6 months

Balance Sheet

Cash and Cash Equivalents

$1,454,460

Investment Securities

$0

Total Investments

$0

Accounts and Notes Receivable

$1,448,280

Loans

$0

Property, Plant and Equipment (PP&E)

$10,877,848

Property and Equipment

$0

Total Assets

$116,809,133

Accounts Payable & Accrued Liabilities

$3,759,818

Policy Liabilities and Accruals

$0

Deposits

$0

Long Term Debt

$20,770,795

Total Liabilities

$30,707,690

Total Stockholders' Equity

$86,101,443

Total Liabilities and Equity

$116,809,133

Statement of Comprehensive Income Information

Total Revenues

$21,937,227

Total Interest Income

$0

Costs & Expenses Applicable to Rev

$13,324,284

Total Interest Expenses

$0

Depreciation and Amortization

$1,085,847

Net Income

$-10,905,772

Earnings Per Share - Basic

$-0.14

Earnings Per Share - Diluted

$-0.14

Auditor: BF Borgers CPA PC
Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Total Prior Capital Raised
$12,100,000
VC Backed?
No
Close Date Platform Valuation Total Raised Security Type Status Reg Type
03/10/2023 Dalmore Group $133,057,658 $18,974 Equity - Common Funded RegA+
Create a free account today to gain access to Kingscrowd analytics.
Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Item 9 Labs on Dalmore Group 2022
Platform: Dalmore Group
Security Type: Equity - Common
Valuation: $133,057,658
Price per Share: $1.40

Follow company

Follow Item 9 Labs on Dalmore Group 2022

Buy Item 9 Labs's Deal Report

Warning: according to the close date for this deal, Item 9 Labs may no longer be accepting investments.

Item 9 Labs Deal Report

Get Kingscrowd's comprehensive report on Item 9 Labs including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Item 9 Labs is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Item 9 Labs deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge